Posted on July 18, 2011 by Sitemaster
The results of the French Genito-Urinary Tumor Group (GETUG) P01 trial — a Phase II study of carboplatin and etoposide in men with progressive metastatic castration-resistant prostate cancer (mCRPC) — have shown that this form of combination chemotherapy has limited efficacy and an unacceptably high toxicity in men with late stage prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: carboplatin, castration-rsistant, etopside, mCRPC, metastasis, neuroendocine | Leave a comment »
Posted on February 24, 2009 by Sitemaster
We have dealt separately with an article on the way in which surgical technique appears to affect the likelihood of positive surgical margins after robot-assisted laparoscopic prostatectomy (RALP). Other reports today cover:
- Whether multifocal tumors are “riskier” that single prostate cancer tumors
- The role of n-3 fatty acids in prevention of selected cancers (including prostate cancer)
- Lycopene in prevention and treatment of prostate cancer
- Serum cholesterol levels and prostate cancer
- Different forms of imaging for prostate cancer localization during EBRT
- Carboplatin + etopside chemotherapy in late-stage metastatic disease … READ MORE …
Filed under: Management, Prevention, Risk, Treatment, Uncategorized | Tagged: carboplatin, cholesterol, etopside, localization, lycopene, multifocal, n-3 fatty acids, unifocal | Leave a comment »
Posted on January 30, 2009 by Sitemaster
Items covered in this weekend news report include:
- Acrylamide exposure as a potential risk for prostate cancer
- The relative merits of three standard first-line therapies in intermediate risk prostate cancer
- Estramustine + etopside in hormone-refractory prostate cancer (HRPC)
- Bone turnover markers and risk for skeletal-related events in patients receiving zoledronic acid … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: acrylamide, bone turnover markers, brachytherapy, carcinogen, estramustine, etopside, external beam radiation, HRPC, risk, skeletal-related events, SREs, surgery | Leave a comment »
